biostudies-literatureBloos FBundesministerium für Bildung und ForschungDeutsche ForschungsgemeinschaftUniversitätsklinikum Jena865-875https://www.ebi.ac.uk/biostudies/studies/S-EPMC9273538biostudies-literatureUnknown48(7)<h4>Purpose</h4>To investigate whether (1 → 3)-β-d-Glucan (BDG)-guidance shortens time to antifungal therapy and thereby reduces mortality of sepsis patients with high risk of invasive Candida infection (ICI).<h4>Methods</h4>Multicenter, randomized, controlled trial carried out between September 2016 and September 2019 in 18 intensive care units enrolling adult sepsis patients at high risk for ICI. Patients in the control group received targeted antifungal therapy driven by culture results. In addition to targeted therapy, patients in the BDG group received antifungals if at least one of two consecutive BDG samples taken during the first two study days was ≥ 80 pg/mL. Empirical antifungal therapy was discouraged in both groups. The primary endpoint was 28-day-mortality.<h4>Results</h4>339 Intensive care medicine(1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial.PMC927353839071386001EO1502PU219/2-3Simon PSchadler DSepNet Study Groupde Heer GWeiler NMeybohm PHempel GWehrfritz AZarbock ALehmann TThomas-Ruddel DBauer MZacharowski KLindau SMotsch JRichter DCornely OAMorer OSchmidt SMoerer OWiedenbeck CWeyland ASchlattmann PMutlak HWeiss RDruner MJaschinski UGunther UHelmer PKranzlein DHeld JCastellanos IWalter GKogelmann KKuhn SOJarczak DPutensen CKurzai OBloos FKluge SRohe GGrundling MWeigand MAfalse(1 → 3)-β-D-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial.<h4>Purpose</h4>To investigate whether (1 → 3)-β-d-Glucan (BDG)-guidance shortens time to antifungal therapy and thereby reduces mortality of sepsis patients with high risk of invasive Candida infection (ICI).<h4>Methods</h4>Multicenter, randomized, controlled trial carried out between September 2016 and September 2019 in 18 intensive care units enrolling adult sepsis patients at high risk for ICI. Patients in the control group received targeted antifungal therapy driven by culture results. In addition to targeted therapy, patients in the BDG group received antifungals if at least one of two consecutive BDG samples taken during the first two study days was ≥ 80 pg/mL. Empirical antifungal therapy was discouraged in both groups. The primary endpoint was 28-day-mortality.<h4>Results</h4>339 2022-01-01T00:00:00Z2022 Jul2026-07-14T20:49:56.041Z2022-07-19T22:48:00.136ZS-EPMC92735383570875810.1007/s00134-022-06733-x